Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose selinexor for severe COVID-19
MOH_2020-04-07_008823Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing XPOVIO plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Safety and activity of low-dose oral selinexor. Started Apr 2020; status: completed.
02
Drugs
selinexor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-04-07_008823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-07_008823.